Cargando…

Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer

Tamoxifen (TAM) resistance is a major challenge in the treatment of estrogen receptor-positive (ER(+)) breast cancer. To date, to the best of our knowledge, there are only a few studies available examining the response of patients with TAM-resistant breast cancer to chemotherapy, and the guidelines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Rui, Guo, Shipeng, Yang, Chengcheng, Sun, Lu, Zong, Beige, Li, Kang, Liu, Li, Tu, Gang, Liu, Manran, Liu, Shengchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050981/ https://www.ncbi.nlm.nih.gov/pubmed/32319562 http://dx.doi.org/10.3892/ijo.2020.4987

Ejemplares similares

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells
por: Liu, Li, et al.
Publicado: (2021)

CXCL1 stimulates migration and invasion in ER-negative breast cancer cells via activation of the ERK/MMP2/9 signaling axis
por: Yang, Chengcheng, et al.
Publicado: (2019)

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer
por: Mo, Zhiqiang, et al.
Publicado: (2013)

MED16 Promotes Tumour Progression and Tamoxifen Sensitivity by Modulating Autophagy through the mTOR Signalling Pathway in ER-Positive Breast Cancer
por: Li, Han, et al.
Publicado: (2022)

HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance
por: Zong, Beige, et al.
Publicado: (2021)

HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance
por: Zong, Beige, et al.
Publicado: (2021)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells
por: Yuan, Jie, et al.
Publicado: (2015)

Although it's painful: The importance of stringent antibody validation
por: Meliopoulos, Victoria A., et al.
Publicado: (2018)

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
por: Chen, Rui, et al.
Publicado: (2018)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Behçet disease – although rare can be present in children
por: Stancu, Aurelia
Publicado: (2014)

Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
por: Wang, Yihua, et al.
Publicado: (2021)

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
por: Zheng, XQ, et al.
Publicado: (2013)

Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression
por: Li, Yuanyuan, et al.
Publicado: (2017)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
por: Bekele, Raie T., et al.
Publicado: (2016)

Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis
por: Li, Zhongrui, et al.
Publicado: (2022)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

Assessment of the Predictive Role of Serum Lipid Profiles in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Qu, Fanli, et al.
Publicado: (2020)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

AGR3 promotes estrogen receptor-positive breast cancer cell proliferation in an estrogen-dependent manner
por: Jian, Lei, et al.
Publicado: (2020)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

It’s not my fault although it might be: chiropractic practice and vicarious liability
por: Simpson, J. Keith, et al.
Publicado: (2021)

Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells
por: Zhang, Yingzi, et al.
Publicado: (2021)

Paeoniflorin Enhances the Sensitivity of ER-Positive Breast Cancer Cells to Tamoxifen through Promoting Sirtuin 4
por: Zhang, Pei, et al.
Publicado: (2022)

SIRT4 enhances the sensitivity of ER‐positive breast cancer to tamoxifen by inhibiting the IL‐6/STAT3 signal pathway
por: Xing, Jilin, et al.
Publicado: (2019)

Dynamic surveillance of tamoxifen‐resistance in ER‐positive breast cancer by CAIX‐targeted ultrasound imaging
por: Li, Ying, et al.
Publicado: (2020)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
por: Qu, Chao, et al.
Publicado: (2019)

ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization
por: Wrobel, Kinga, et al.
Publicado: (2016)

Liver hyperplasia after tamoxifen induction of Myc in a transgenic medaka model
por: Menescal, Luciana A., et al.
Publicado: (2012)

Although with intact mucosa at colonoscopy, chagasic megacolons have an overexpression of Gal-3
por: Garvil, Mariana Pacífico, et al.
Publicado: (2020)

The clinical translation of eicosanoids and other oxylipins, although challenging, should be actively pursued
por: Gladine, Cécile, et al.
Publicado: (2021)

Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models
por: Zou, Wei, et al.
Publicado: (2015)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_93u1liflbp76jsqp5n3b39gasa